

Publication of study showing BLASTX™ increases the efficacy of Negative Pressure Wound Therapy

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today announces the publication of a study which found BLASTX™ to be efficacious in the treatment of pressure ulcers when used in conjunction with negative pressure wound therapy (NPWT).

Next Science is a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health.

The study entitled “A Diagnostic-Driven Prospective Clinical Study Evaluating the Combination of an Antibiofilm Agent and Negative Pressure Wound Therapy” by Dr Thomas E. Serena MD et al., has been published in *Diagnostics*, an international peer-reviewed journal.¹

It can be accessed via the following link. <https://www.mdpi.com/journal/diagnostics>

The primary objective of the prospective study was to determine whether adding an anti-microbial agent would decrease both planktonic and biofilm bacteria in a wound and increase the efficacy of NPWT. Fluorescence imaging was used to track bacterial burden and inform therapy. The 20-patient study focused on the treatment of pressure ulcers which affects millions of people in the United States each year.

The study found that 45% of the pressure ulcers reduced in size over the four-week study with “a resolution of bacterial fluorescence in the NPWT dressing and wound bed seen in an average of three weeks”.

Dr Serena concluded that the combination of BLASTX™ and NPWT “reduced bacterial levels and improved wound healing in recalcitrant pressure ulcers”.

Next Science’s CEO and Managing Director I.V. Hall said: “The study by leading wound care specialist Dr Thomas Serena shows that the use of BLASTX™ should be considered when treating pressure ulcers with NPWT. The results have been through a peer review process and their publication in *Diagnostics*, an international journal adds to the growing clinical evidence highlighting the efficacy of BLASTX™ in improving health outcomes for patients. We will continue to work closely with the medical community to conduct clinical research that further investigates the effectiveness of Next Science’s products.”

Approved and authorised for release by the Managing Director.

¹ In addition to Dr Thomas Serena, cited authors include Emily King, Laura M. Serena, Kristy Breisinger, Omar Al-Jalodi and Matthew Myntti.

NEXT SCIENCE®

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.